Back to Agenda
Parallel Session 5B: Rare Diseases
Session Chair(s)
Yazeed AlRuthia
Professor, Department of Clinical Pharmacy, King Saud University, College of Pharmacy, Saudi Arabia
Niveen Osman, MBA
Regulatory Affairs Director Middle East & Africa, Amgen Inc., United Arab Emirates
The regulation and treatment of rare diseases have become a growing priority in the MENA region, where limited access to orphan drugs can create challenges for patient access. This session will focus on advancing regulatory and strategic plans for rare diseases and orphan drugs in the MENA region, with key insights from the Saudi FDA, experiences from national health systems, and international best practices.
Speaker(s)
Virginie Hivert, PHARMD, PHD
Therapeutic Development Director, Eurordis-Rare Diseases Europe, France
Patient Access to Orphan Drugs in European National Health Systems: Learned Lessons
Eric Obscherning
Director, Health & Life Sciences, Access Partnership, United States
Patient-Centric Care for Rare Diseases
Maurille Feudjo Tepie
VP & Head, GLobal RWE and Digital Sciences, UCB, United Kingdom
Marco Rafael, PHARMD, MBA, RPH
Regulatory Policy Leader, Roche, Switzerland
Panel Discussion with QandA
Kristina Larsson, MS
Head of Orphan Medicines, Division for Human Medicines Evidence Generation, European Medicines Agency, Netherlands
Panel Discussion with QandA
Abeer Elbehairy
General Manager - Drug Utilization & Pharmacy Practice G.A, Egyptian Drug Authority (EDA), Egypt
Panel Discussion with QandA
Have an account?